Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

CVRx, Inc. CVRX

Healthcare  —  Medical Devices
2.70 0.17 6.72% as of 25 Sep
Market cap
$67.4M
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

CVRx, Inc. (CVRX) Business Profile

Updated before January 2025

Company Overview

CVRx, Inc. (CVRX) is a pioneering medical technology company specializing in innovative neuromodulation solutions for cardiovascular diseases. Founded in 2001 and headquartered in Minneapolis, Minnesota, CVRx has established itself as a leader in the development of implantable devices designed to improve the quality of life for patients suffering from chronic heart failure and other cardiovascular conditions. The company was founded by a team of medical professionals and engineers with a vision to revolutionize the treatment of heart-related ailments through cutting-edge technology.

The leadership team at CVRx is composed of seasoned professionals with extensive experience in the medical device and healthcare industries. The company’s CEO, Nadim Yared, has been at the helm since 2006, bringing a wealth of expertise in medical technology and strategic growth. Under his leadership, CVRx has achieved significant milestones, including FDA approvals and successful commercialization of its flagship products.

Core Business Segments

Barostim Therapy

CVRx’s primary product offering is the Barostim™ system, a groundbreaking neuromodulation device designed to treat chronic heart failure and resistant hypertension. Barostim is the first FDA-approved device of its kind, leveraging the body’s natural mechanisms to improve cardiovascular function. The system works by stimulating the baroreceptors in the carotid artery, which helps regulate blood pressure and heart function.

Key Features of Barostim:

  • Heart Failure Treatment: Barostim is specifically designed for patients with reduced ejection fraction heart failure, offering an alternative to traditional drug therapies.
  • Hypertension Management: The device is also effective in managing resistant hypertension, providing relief for patients who do not respond to conventional treatments.
  • Non-Invasive Approach: Unlike other treatment options, Barostim does not require invasive surgical procedures, making it a safer and more accessible solution for patients.

Support Services

In addition to its flagship product, CVRx offers a range of support services to ensure optimal patient outcomes. These services include:

  • Patient Education: Comprehensive resources to help patients understand their condition and the benefits of Barostim therapy.
  • Physician Training: Specialized training programs for healthcare providers to ensure proper device implantation and patient management.
  • Technical Support: Ongoing technical assistance to address any issues related to the device or its operation.

Business Model

CVRx operates on a business model that combines product innovation with robust support services to drive revenue growth. The company generates revenue primarily through the sale of its Barostim devices and related accessories. Additionally, CVRx offers training and support services to healthcare providers, creating a recurring revenue stream.

The company’s approach to business is centered on collaboration with healthcare professionals, patients, and regulatory bodies to ensure the safety and efficacy of its products. By focusing on a niche market with high unmet medical needs, CVRx has positioned itself as a leader in the neuromodulation space.

Strategic Direction

CVRx is committed to expanding its market presence and driving innovation in the field of cardiovascular neuromodulation. The company’s strategic priorities include:

  • Geographic Expansion: CVRx aims to increase its footprint in international markets, particularly in Europe and Asia, where the demand for advanced cardiovascular treatments is growing.
  • Product Development: The company is investing heavily in research and development to enhance the capabilities of its existing products and explore new applications for its technology.
  • Sustainability Goals: CVRx is dedicated to minimizing its environmental impact by adopting sustainable manufacturing practices and reducing waste.
  • Partnerships and Collaborations: The company is actively seeking partnerships with academic institutions, healthcare providers, and other medical device companies to accelerate innovation and improve patient outcomes.

Competitive Landscape

CVRx operates in a highly competitive market, facing competition from both established medical device companies and emerging startups. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of cardiovascular devices.
  • Boston Scientific: Known for its innovative solutions in cardiology and neuromodulation.
  • Abbott Laboratories: A major player in the cardiovascular device market, with a strong focus on heart failure treatments.
  • Biotronik: Specializes in implantable devices for cardiac rhythm management and vascular intervention.

Despite the competition, CVRx differentiates itself through its unique Barostim technology, which addresses unmet medical needs and offers a non-invasive alternative to traditional treatments.

Risk Factors

Like any medical device company, CVRx faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Regulatory Challenges: The company’s products are subject to stringent regulatory requirements, and any delays or issues in obtaining approvals could hinder market access.
  • Market Dependence: CVRx relies heavily on the success of its Barostim system, making it vulnerable to market fluctuations and changes in demand.
  • Supply Chain Disruptions: Global supply chain issues, including shortages of critical components, could affect the company’s ability to manufacture and deliver its products.
  • Competition: Intense competition from larger, well-established companies could limit CVRx’s market share and pricing power.

Recent Developments

In recent years, CVRx has achieved several notable milestones, including:

  • FDA Approval: The Barostim system received FDA approval for the treatment of heart failure, marking a significant achievement for the company.
  • Clinical Trials: CVRx has conducted extensive clinical trials to demonstrate the safety and efficacy of its products, further solidifying its position as a leader in the field.
  • Global Expansion: The company has expanded its operations to new markets, including Europe and Asia, to meet the growing demand for advanced cardiovascular treatments.
  • Technological Innovations: CVRx continues to invest in research and development to enhance its product offerings and explore new applications for its technology.

Investment Considerations

Strengths:

  • Innovative Technology: CVRx’s Barostim system is a first-of-its-kind device with significant potential to disrupt the cardiovascular treatment market.
  • Strong Leadership: The company’s experienced management team has a proven track record of driving growth and innovation.
  • Growing Market: The global market for cardiovascular devices is expanding, providing ample opportunities for CVRx to grow its business.

Risks:

  • Regulatory Hurdles: The company’s reliance on regulatory approvals poses a significant risk to its operations.
  • Market Concentration: Dependence on a single product line could limit growth opportunities and increase vulnerability to market changes.
  • Competitive Pressure: Intense competition from larger players could impact CVRx’s market share and profitability.

Conclusion

CVRx, Inc. is a trailblazer in the field of cardiovascular neuromodulation, offering innovative solutions to address unmet medical needs. With its groundbreaking Barostim system, the company has established itself as a leader in the treatment of chronic heart failure and resistant hypertension. While CVRx faces challenges such as regulatory hurdles and competitive pressure, its strong leadership, innovative technology, and strategic growth initiatives position it for long-term success. As the global demand for advanced cardiovascular treatments continues to rise, CVRx is well-positioned to capitalize on these opportunities and drive sustainable growth.